TENADINIR - CÔNG TY CỔ PHẦN GLOBAL PHARMACEUTICAL

TENADINIR - CÔNG TY CỔ PHẦN GLOBAL PHARMACEUTICAL

TENADINIR - CÔNG TY CỔ PHẦN GLOBAL PHARMACEUTICAL

TENADINIR - CÔNG TY CỔ PHẦN GLOBAL PHARMACEUTICAL

global pharmaceutical

GLOBAL PHARMACEUTICAL JOINT-STOCK COMPANY

TAKE CARE OF COMMUNITY HEALTH

 global pharmaceutical
Advice and support

0981314599

TENADINIR
TENADINIR

TENADINIR

Present

Box 2 blisters x 10 capsules

Ingredient

Cefdinir 300mg. Excipients q.s for 1 hard capsules

Point

Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
   
DETAIL

TENADINIR

Keep out of reach of children. Read the manual carefully before use

If need more information please consult with your doctor

COMPOSITION:

Cefdinir 300mg. Excipients q.s for 1 hard capsules

INDICATIONS AND USAGE:

Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

Adults and Adolescents:

Community-Acquired Pneumonia:

Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains)

Acute Exacerbations of Chronic Bronchitis:

Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).

Acute Maxillary Sinusitis:

Caused by Haemophilus influenzae (including β-lactamase producing strains), 

Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).

NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. 

Uncomplicated Skin and Skin Structure Infections:

Caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes

Pediatric Patients:

Acute Bacterial Otitis Media:

Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).

Pharyngitis/Tonsillitis:

Caused by Streptococcus pyogenes 

NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. 

Uncomplicated Skin and Skin Structure Infections:

Caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes

CONTRAINDICATIONS:

Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

OTHER INFORMATION: Please refer to the Instruction sheet included in the package

MANUFACTURERMEDIPHARCO JOINT-STOCK COMPANY

DISTRIBUTOR: GLOBAL PHARMACEUTICAL JOINT-STOCK COMPANY

 

OTHER PRODUCTS
HOT NEWS
SHAREHOLDERS NEWS